Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker IVA
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Oct 27, 2026 | SCHEDULE 13G/A (amended) | IVA Inventiva S.A. | Francois Xavier Mauron | 15.93M | 6.7% | SCHEDULE 13G/A ↗ |
| Oct 27, 2026 | SCHEDULE 13G/A (amended) | IVA Inventiva S.A. | Stephane Bergez | 15.93M | 6.7% | SCHEDULE 13G/A ↗ |
| Oct 27, 2026 | SCHEDULE 13G/A (amended) | IVA Inventiva S.A. | BioDiscovery 6 FPCI | 15.93M | 6.7% | SCHEDULE 13G/A ↗ |
| Oct 27, 2026 | SCHEDULE 13G/A (amended) | IVA Inventiva S.A. | Andera Partners | 15.93M | 6.7% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | IVA Inventiva S.A. | David Kroin | 7.80M | 3.8% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | IVA Inventiva S.A. | Deep Track Biotechnology Master Fund, Ltd. | 7.80M | 3.8% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | IVA Inventiva S.A. | Deep Track Capital, LP | 7.80M | 3.8% | SCHEDULE 13G/A ↗ |
| Apr 1, 2026 | SCHEDULE 13D/A (amended) | IVA Inventiva S.A. | Rick Yang | 9.37M | 4.9% | SCHEDULE 13D/A ↗ |
| Apr 1, 2026 | SCHEDULE 13D/A (amended) | IVA Inventiva S.A. | Paul Walker | 9.37M | 4.9% | SCHEDULE 13D/A ↗ |
| Apr 1, 2026 | SCHEDULE 13D/A (amended) | IVA Inventiva S.A. | Scott D. Sandell | 9.37M | 4.9% | SCHEDULE 13D/A ↗ |
| Apr 1, 2026 | SCHEDULE 13D/A (amended) | IVA Inventiva S.A. | Edward T. Mathers | 9.37M | 4.9% | SCHEDULE 13D/A ↗ |
| Apr 1, 2026 | SCHEDULE 13D/A (amended) | IVA Inventiva S.A. | Mohamad H. Makhzoumi | 9.37M | 4.9% | SCHEDULE 13D/A ↗ |
| Apr 1, 2026 | SCHEDULE 13D/A (amended) | IVA Inventiva S.A. | Anthony A. Florence, Jr. | 9.37M | 4.9% | SCHEDULE 13D/A ↗ |
| Apr 1, 2026 | SCHEDULE 13D/A (amended) | IVA Inventiva S.A. | Carmen Chang | 9.37M | 4.9% | SCHEDULE 13D/A ↗ |
| Apr 1, 2026 | SCHEDULE 13D/A (amended) | IVA Inventiva S.A. | Ali Behbahani | 9.37M | 4.9% | SCHEDULE 13D/A ↗ |
| Apr 1, 2026 | SCHEDULE 13D/A (amended) | IVA Inventiva S.A. | Forest Baskett | 9.37M | 4.9% | SCHEDULE 13D/A ↗ |
| Apr 1, 2026 | SCHEDULE 13D/A (amended) | IVA Inventiva S.A. | Nea 18 Vge GP, LLC | 9.37M | 4.9% | SCHEDULE 13D/A ↗ |
| Apr 1, 2026 | SCHEDULE 13D/A (amended) | IVA Inventiva S.A. | NEA Partners 18 VGE, L.P. | 9.37M | 4.9% | SCHEDULE 13D/A ↗ |
| Apr 1, 2026 | SCHEDULE 13D/A (amended) | IVA Inventiva S.A. | NEA 18 Venture Growth Equity, L.P. | 9.37M | 4.9% | SCHEDULE 13D/A ↗ |
| Apr 1, 2026 | SCHEDULE 13D/A (amended) | IVA Inventiva S.A. | Growth Equity Opportunities 18 VGE, LLC | 9.37M | 4.9% | SCHEDULE 13D/A ↗ |
| Apr 1, 2026 | SCHEDULE 13D/A (amended) | IVA Inventiva S.A. | Nea 17 GP, LLC | 9.37M | 4.9% | SCHEDULE 13D/A ↗ |
| Apr 1, 2026 | SCHEDULE 13D/A (amended) | IVA Inventiva S.A. | NEA Partners 17, L.P. | 9.37M | 4.9% | SCHEDULE 13D/A ↗ |
| Apr 1, 2026 | SCHEDULE 13D/A (amended) | IVA Inventiva S.A. | New Enterprise Associates 17, L.P. | 9.37M | 4.9% | SCHEDULE 13D/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | IVA Inventiva S.A. | Francois Xavier Mauron | 14.11M | 7.7% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | IVA Inventiva S.A. | Stephane Bergez | 14.11M | 7.7% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | IVA Inventiva S.A. | BioDiscovery 6 FPCI | 14.11M | 7.7% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | IVA Inventiva S.A. | Andera Partners | 14.11M | 7.7% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | IVA Inventiva S.A. | Ms. Lillian Nordahl | 6.78M | 3.5% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | IVA Inventiva S.A. | Dr. Jeffrey R. Jay, M.D. | 6.78M | 3.5% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | IVA Inventiva S.A. | Great Point Partners, LLC | 6.78M | 3.5% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | IVA Inventiva S.A. | Jacques Theurillat | 12.33M | 5.6% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | IVA Inventiva S.A. | Joseph Anderson | 19.09M | 8.6% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | IVA Inventiva S.A. | Kinam Hong | 19.09M | 8.6% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | IVA Inventiva S.A. | Cedric Moreau | 19.09M | 8.6% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | IVA Inventiva S.A. | Antoine Papiernik | 19.09M | 8.6% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | IVA Inventiva S.A. | Sofinnova Partners SAS, a French corporation | 19.09M | 8.6% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | IVA Inventiva S.A. | Sofinnova Crossover II SLP | 6.75M | 3.1% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | IVA Inventiva S.A. | Sofinnova Crossover I SLP | 12.33M | 5.6% | SCHEDULE 13G/A ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | IVA Inventiva S.A. | Robin C. John | 9.37M | 4.6% | SCHEDULE 13G/A ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | IVA Inventiva S.A. | Finny Kuruvilla, M.D. Ph. D. | 9.37M | 4.6% | SCHEDULE 13G/A ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | IVA Inventiva S.A. | Eventide Asset Management, LLC | 9.37M | 4.6% | SCHEDULE 13G/A ↗ |
| Jan 30, 2026 | SCHEDULE 13G | IVA Inventiva S.A. | David Kroin | 11.67M | 6.1% | SCHEDULE 13G ↗ |
| Jan 30, 2026 | SCHEDULE 13G | IVA Inventiva S.A. | Deep Track Biotechnology Master Fund, Ltd. | 11.67M | 6.1% | SCHEDULE 13G ↗ |
| Jan 30, 2026 | SCHEDULE 13G | IVA Inventiva S.A. | Deep Track Capital, LP | 11.67M | 6.1% | SCHEDULE 13G ↗ |
| Nov 19, 2025 | SCHEDULE 13D/A (amended) | IVA Inventiva S.A. | Srinivas Akkaraju | 13.54M | 7.4% | SCHEDULE 13D/A ↗ |
| Nov 19, 2025 | SCHEDULE 13D/A (amended) | IVA Inventiva S.A. | Samsara Opportunity Fund GP, LLC | 5.19M | 2.8% | SCHEDULE 13D/A ↗ |
| Nov 19, 2025 | SCHEDULE 13D/A (amended) | IVA Inventiva S.A. | Samsara Opportunity Fund, L.P. | 5.19M | 2.8% | SCHEDULE 13D/A ↗ |
| Nov 19, 2025 | SCHEDULE 13D/A (amended) | IVA Inventiva S.A. | Samsara BioCapital GP, LLC | 8.35M | 4.5% | SCHEDULE 13D/A ↗ |
| Nov 19, 2025 | SCHEDULE 13D/A (amended) | IVA Inventiva S.A. | Samsara BioCapital, L.P. | 8.35M | 4.5% | SCHEDULE 13D/A ↗ |
| Nov 19, 2025 | SCHEDULE 13D/A (amended) | IVA Inventiva S.A. | Mark N. Lampert | 9.57M | 5.0% | SCHEDULE 13D/A ↗ |
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 10:01 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances